Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia
Nexalin Technology's Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer's Disease and Dementia This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin's frequency neurostimulator as a potential non-invasive therapy for cognitive disorders associated with Alzheimer's disease GlobeNewswire November 05, 2025 HOUSTON, TX, Nov. […]